P&G
27.3.2020 15:16:05 CET | Business Wire | Press release
Today the Procter & Gamble Company (NYSE:PG) announced donations totalling $10 million USD in personal health and hygiene, household products, sanitizers and financial support to help people in need, including families, elderly citizens and health professionals, enabling access to everyday essentials. As part of this effort, P&G is donating $1 million to support the International Federation of Red Cross and Red Crescent Societies’ (IFRC) COVID-19 appeal, as well as individual European Red Cross Red Crescent national societies’ efforts, to improve the lives of Europe’s vulnerable people across the continent during these challenging times.
Since the onset of the outbreak, P&G has been working with long-standing partner organizations to understand how to best support communities, relief agencies and those impacted by this global emergency. Today, we are taking three immediate actions to support urgent public needs.
Supporting vital health care services: We will donate an initial one million dollars to the IFRC and Red Cross Red Crescent National Societies to provide health care, medical supplies and hygiene education to vulnerable people across Europe.
IFRC Regional Director for Europe (ad interim), Elkhan Rahimov, said the donation would enable Red Cross and Red Crescent volunteers and staff across Europe to continue their vital and lifesaving work on the frontline of the COVID19 response.
“In these times of great emergency, this support will enable us to keep helping the most vulnerable in our society. Older people and immune compromised, those in quarantine and isolation, migrants and the homeless. We are truly appreciative of Procter and Gamble’s support,” Mr Rahimov said.
Improving lives at home with everyday essentials: Everyone at P&G is working diligently to maintain the production, distribution and availability of all our brands, not only for consumers but also for the comfort and confidence of the medical workers, emergency services and first responders who are on the frontline of the battle against COVID-19. We are also working with Red Cross and Red Crescent National Societies and local foodbanks, to deliver everyday cleaning, health and hygiene essentials to those who need it most. During these unprecedented times, our brands enable people to do the simple things – brush their teeth, wash their hair, shave, wear a clean shirt, change a baby diaper, keep homes and clothes clean – actions that can help restore a sense of normalcy and improve everyday life and wellbeing.
Providing hand and surface sanitizers: We are shifting manufacturing to help protect frontline workers. We recently started producing sanitizer in several P&G manufacturing sites in Europe, to ensure our people can continue operating safely and supporting hospitals, health authorities and relief organizations. We are building capacity to provide a minimum of 10,000 litres of hand sanitizer in 16 countries around Europe, enabling more than 3 million hand washes per week.
Loic Tassel, P&G President, Europe said, “In 30 years of working in the consumer goods industry, I have never experienced such challenging times impacting far more than businesses, but our neighbours, our communities – every facet of our lives. The P&G team is committed to doing everything possible to ensure the health and safety of all our employees, to continue to serve our consumers with essential products and services and to take meaningful action to help communities in need and those on the frontlines. Together, P&G and its organization partners are stepping up as a force for good in service to our communities.”.
We cannot predict how and when this crisis will end but we’re committed to be part of the solution. We have mobilized the full capabilities of P&G and our partners to help out in this time of need, and we will be there for our employees, consumers and communities — stepping up to be a force for good – however long it takes.
– ENDS –
Notes to the Editor
Visit https://www.pg.com/covid19 to learn how we’re stepping up to serve during the COVID-19 crisis.
About International Federation of Red Cross and Red Crescent Societies
About IFRC
IFRC is the world’s largest humanitarian network, comprising 192 National Red Cross and Red Crescent Societies working to save lives and promote dignity around the world.
www.ifrc.org - Facebook - Twitter - YouTube
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always® , Ambi Pur® , Ariel® , Bounty® , Charmin® , Crest® , Dawn® , Downy® , Fairy® , Febreze® , Gain® , Gillette® , Head & Shoulders® , Lenor® , Olay® , Oral-B® , Pampers® , Pantene® , SK-II® , Tide® , Vicks® , and Whisper® . The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com/ for the latest news and information about P&G and its brands.
To learn more, follow us on Twitter , LinkedIn , Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200327005286/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom